Dana Flanders
Stock Analyst at Guggenheim
(0.10)
# 4,413
Out of 5,072 analysts
7
Total ratings
16.67%
Success rate
-20.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dana Flanders
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VALN Valneva SE | Maintains: Buy | $17 → $15 | $9.54 | +57.23% | 1 | Mar 24, 2025 | |
| SCYX SCYNEXIS | Initiates: Buy | $25 | $0.68 | +3,586.23% | 1 | Jan 22, 2021 | |
| PCRX Pacira BioSciences | Initiates: Neutral | n/a | $23.81 | - | 1 | May 27, 2020 | |
| HRTX Heron Therapeutics | Initiates: Buy | $24 | $1.12 | +2,042.86% | 1 | May 27, 2020 | |
| COLL Collegium Pharmaceutical | Initiates: Neutral | n/a | $46.23 | - | 1 | May 27, 2020 | |
| EBS Emergent BioSolutions | Upgrades: Buy | $60 → $75 | $11.05 | +578.73% | 2 | Nov 2, 2018 |
Valneva SE
Mar 24, 2025
Maintains: Buy
Price Target: $17 → $15
Current: $9.54
Upside: +57.23%
SCYNEXIS
Jan 22, 2021
Initiates: Buy
Price Target: $25
Current: $0.68
Upside: +3,586.23%
Pacira BioSciences
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $23.81
Upside: -
Heron Therapeutics
May 27, 2020
Initiates: Buy
Price Target: $24
Current: $1.12
Upside: +2,042.86%
Collegium Pharmaceutical
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $46.23
Upside: -
Emergent BioSolutions
Nov 2, 2018
Upgrades: Buy
Price Target: $60 → $75
Current: $11.05
Upside: +578.73%